Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

Innovation & Research

Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

Our pipeline refers to drugs in development, including those in preclinical testing, clinical development, regulatory approval and lifecycle management.

The information in the table reflects Menarini's development pipeline and is not intended for promotional or marketing purposes. The safety and efficacy of the investigational compounds, or investigational uses of marketed products have not been established and marketing approval has yet to be granted by regulatory authorities.

ONCOLOGY

Legenda
  • ABSSSI: Acute Bacterial Skin and Skin Structure Infections
  • ADC: Antibody Drug Conjugate
  • CABP: Community Acquired Bacterial Pneumonia
  • cIAI: Complicated Intra-Abdominal Infections
  • cUTI: Complicated Urinary Tract Infections
  • ER: Estrogen Receptor
  • HABP: Hospital Acquired Bacterial Pneumonia
  • IV: Intravenous
  • PIM/FLT3i: PIM/FLT3 Kinase Inhibitor
  • PI3Ki: Phosphatidylinositol 3-Kinase Inhibitor
  • RETi: RET Kinase Inhibitor
  • SME: Small Molecule Entity
  • VABP: Ventilator Associated Bacterial Pneumonia
  • XPO1i: XPO1 Inhibitor
  • P: Preclinical
  • I: Phase I
  • II: Phase II
  • III: Phase III
  • F: Filing
  • A: Approval

ANTI-INFECTIVES

Legenda
  • ABSSSI: Acute Bacterial Skin and Skin Structure Infections
  • ADC: Antibody Drug Conjugate
  • CABP: Community Acquired Bacterial Pneumonia
  • cIAI: Complicated Intra-Abdominal Infections
  • cUTI: Complicated Urinary Tract Infections
  • ER: Estrogen Receptor
  • HABP: Hospital Acquired Bacterial Pneumonia
  • IV: Intravenous
  • PIM/FLT3i: PIM/FLT3 Kinase Inhibitor
  • PI3Ki: Phosphatidylinositol 3-Kinase Inhibitor
  • RETi: RET Kinase Inhibitor
  • SME: Small Molecule Entity
  • VABP: Ventilator Associated Bacterial Pneumonia
  • XPO1i: XPO1 Inhibitor
  • P: Preclinical
  • I: Phase I
  • II: Phase II
  • III: Phase III
  • F: Filing
  • A: Approval